What is the clinical impact of low plasminogen activator inhibitor-1 (PAI-1) activity? A case report and study of the incidence of low PAI-1 antigen in a healthy population [6]

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 7, 2007, Pages 1565-1566

  Santamaría, Amparo ^a   Borrell, M ^a   Mateo, J ^a   Vallve, C ^a   Fontcuberta, J ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANEXAMIC ACID;

ADULT; ANAMNESIS; ANTIGEN DETECTION; BLEEDING TENDENCY; BLOOD ANALYSIS; BLOOD CLOTTING TEST; BLOOD DONOR; BLOOD SAMPLING; CLINICAL FEATURE; DISEASE DURATION; FEMALE; HUMAN; INCIDENCE; LABORATORY TEST; LETTER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; THROMBOCYTE FUNCTION;

ADOLESCENT; ADULT; FEMALE; FIBRINOLYSIS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; REFERENCE VALUES; RISK FACTORS;

EID: 34250752724     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02585.x     Document Type: Letter

References (10)

1. Fay WP, Shapiro AD, Shih JL, Schleef RR, Gingsburg D. Complete deficiency of plasminogen-activator inhibitor type I due to a frame-shift mutation. N Engl J Med 1992; 327: 1729-33.
2. Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: Characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90: 204-8.
3. Kawasaky T, Dewerchin M, Lijnen HR, Vermylen J, Hoylaerts MF. Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood 2000; 96: 153-60.
4. Diéval J, Nguyen G, Gross S, Delobel J, Kruithof EK. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 1991; 77: 528-32.
5. Lee MH, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor results in hiperfibrinolytic bleeding. Blood 1993; 9: 2357-62.
6. Tanimura LK, Weddell JA, McKown CG, Shapiro AD, Mulherin J. Oral management of a patient with a plasminogen activator inhibitor (PAI-1) deficiency: Case report. Pediatr Dent 1994; 16: 133-5.
7. Takahashi Y, Tanaka T, Minowa H, Ookubo Y, Sugimoto M, Nakajima M, Miyauchi Y, Yoshioka A. Hereditary partial deficiency of plasminogen activator inhibitor-1 associated with lifelong bleeding tendency. Int J Hematol 1996; 64: 61-8.
8. Agren A, Wiman B, Stiller V, Lindmarker P, Sten-linder M, Carlsson A, Holmstrom M, Odeberg J, Schulman S. Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis. J Thromb Haemost 2006; 4: 201-8.
9. Souto JC, Almasy L, Borrell M, Gari M, Martínez E, Mateo J, Stone WH, Blangero J, Fontcuberta J. Genetic susceptibility to thombosis and its relationship to physiological risk factors: The GAIT Study. Am J Hum Genet 2000; 101: 1546-51.
10. Mosnier LO, von dem Borne PAK, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact pathway of coagulation. Thromb Haemost 1998; 80: 829-35.